Drug
hMG-HP
hMG-HP is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_4
Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.
NCT02785822
completed
Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
NCT01331720
completed
Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
NCT01331733
completed
Assessment of the Therapeutic Utility of hMG-HP
NCT01330784
Clinical Trials (4)
Showing 4 of 4 trials
NCT02785822Phase 4
Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.
NCT01331720
Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
NCT01331733
Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
NCT01330784
Assessment of the Therapeutic Utility of hMG-HP
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4